Sandoz concludes acquisition of antifungal agent Mycamine from Astellas

Through this acquisition of the global echinocandin, one of three major antifungal classes, Sandoz significantly reinforces its global hospital offering and leading anti-infectives portfolio.

Astellas reported Mycamine sales of JPY 14.2 billion (USD 105 million) for the year ending March 31, 2023. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.

Sandoz CEO Richard Saynor said, “This is another sign of our commitment at Sandoz to driving responsible access to critical antimicrobial medicines. We are both investing in our production network and selectively building out our leading portfolio in this field to ensure that we can continue to offer patients around the world the right medicine at the right time.”

Mycamine has a global patient base of well over two million. It is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in hematology and oncology patients, and widely used in organ transplants.

It is indicated for treatment of invasive candidiasis and esophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.

Read also: Sandoz releases positive results from Mylight Phase lll study for biosimilar Aflibercept

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. The company's broad portfolio of medicines covers all major therapeutic areas.